A detailed history of Vanguard Group Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,654,757 shares of ZNTL stock, worth $21.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,654,757
Previous 4,398,625 28.56%
Holding current value
$21.2 Million
Previous $69.3 Million 66.64%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.09 - $16.13 $5.14 Million - $20.3 Million
1,256,132 Added 28.56%
5,654,757 $23.1 Million
Q1 2024

May 10, 2024

SELL
$10.83 - $16.49 $10.3 Million - $15.7 Million
-951,833 Reduced 17.79%
4,398,625 $69.3 Million
Q4 2023

Feb 14, 2024

BUY
$9.84 - $20.13 $1.12 Million - $2.29 Million
113,795 Added 2.17%
5,350,458 $81.1 Million
Q3 2023

Nov 14, 2023

BUY
$19.63 - $28.29 $6.04 Million - $8.7 Million
307,490 Added 6.24%
5,236,663 $105 Million
Q2 2023

Aug 14, 2023

BUY
$17.41 - $30.05 $12 Million - $20.7 Million
688,558 Added 16.24%
4,929,173 $139 Million
Q1 2023

May 15, 2023

BUY
$16.14 - $24.94 $1.3 Million - $2.01 Million
80,466 Added 1.93%
4,240,615 $72.9 Million
Q4 2022

Feb 10, 2023

BUY
$18.07 - $25.6 $973,756 - $1.38 Million
53,888 Added 1.31%
4,160,149 $83.8 Million
Q3 2022

Nov 14, 2022

SELL
$20.23 - $31.73 $7.81 Million - $12.3 Million
-386,074 Reduced 8.59%
4,106,261 $88.9 Million
Q2 2022

Aug 12, 2022

BUY
$17.91 - $52.25 $22.4 Million - $65.4 Million
1,251,750 Added 38.63%
4,492,335 $126 Million
Q1 2022

May 13, 2022

BUY
$41.58 - $80.89 $2.23 Million - $4.34 Million
53,599 Added 1.68%
3,240,585 $150 Million
Q4 2021

Feb 14, 2022

BUY
$66.92 - $84.79 $3.69 Million - $4.67 Million
55,101 Added 1.76%
3,186,986 $268 Million
Q3 2021

Nov 12, 2021

BUY
$46.83 - $73.5 $13.9 Million - $21.8 Million
297,061 Added 10.48%
3,131,885 $209 Million
Q2 2021

Aug 13, 2021

BUY
$37.41 - $62.25 $106 Million - $176 Million
2,834,824 New
2,834,824 $151 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $214M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.